<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30297384</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>09</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1549-490X</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>08</Day>                    </PubDate>                </JournalIssue>                <Title>The oncologist</Title>                <ISOAbbreviation>Oncologist</ISOAbbreviation>            </Journal>            <ArticleTitle>Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient Carcinoma.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">theoncologist.2018-0279</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1634/theoncologist.2018-0279</ELocationID>            <Abstract>                <AbstractText>Integrase interactor 1 (INI-1)-deficient carcinoma is a rare cancer characterized by the loss of the SWItch/Sucrose Non-Fermentable-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 gene (<i>SMARCB1</i>) and tends to follow an aggressive clinical course. There is no currently available standard therapy option, although a few promising treatment strategies, including enhancer of zeste homolog 2 (EZH2) inhibition, are under active investigation. This report describes a 30-year-old woman with INI-1-deficient carcinoma who progressed on combination chemotherapy and an EZH2 inhibitor. Next-generation-sequencing-based targeted cancer-related gene assay confirmed <i>SMARCB1</i> loss and revealed other mutations in breast cancer 1 gene and checkpoint kinase 2 gene, which may have impacted her clinical course. After discussion at the molecular tumor board, she was offered alisertib, an aurora A kinase inhibitor, on a single-patient expanded-use program and achieved prolonged disease stabilization. Aurora A kinase inhibition may have an important role in the management of patients with INI-1-deficient tumors, warranting further evaluation in clinical studies.</AbstractText>                <AbstractText Label="KEY POINTS" NlmCategory="CONCLUSIONS">Loss of the SWItch/Sucrose Non-Fermentable-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 gene (<i>SMARCB1</i>), which encodes integrase interactor 1 (INI-1), is associated with various mesenchymal malignancies, but a few carcinomas with rhabdoid features have been recently described as a distinct entity.INI-1-deficient carcinoma can be very aggressive, and there is no known treatment option available.There are encouraging preliminary data with an enhancer of zeste homolog 2 inhibitor, tazematostat, in INI-1-deficient malignancies, including INI-1-deficient carcinomas.Loss of INI-1 can activate aurora A kinase (AurkA), and inhibition of AurkA by alisertib could be a viable option and warrants further investigation in this cancer.Clinical genomic profiling can confirm diagnosis of molecularly defined malignancy and provide insights on therapeutic options.</AbstractText>                <CopyrightInformation>Â© AlphaMed Press 2018.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Karantanos</LastName>                    <ForeName>Theodoros</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Radiological Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rooper</LastName>                    <ForeName>Lisa</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology and Radiological Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kang</LastName>                    <ForeName>Youme</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiology and Radiological Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lin</LastName>                    <ForeName>Cheng Ting</ForeName>                    <Initials>CT</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiology and Radiological Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wenga</LastName>                    <ForeName>Pawla</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Radiological Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sagorsky</LastName>                    <ForeName>Sarah</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Radiological Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lauring</LastName>                    <ForeName>Josh</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Radiological Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kang</LastName>                    <ForeName>Hyunseok</ForeName>                    <Initials>H</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5758-8202</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Radiological Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA hkang30@jhmi.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Oncologist</MedlineTA>            <NlmUniqueID>9607837</NlmUniqueID>            <ISSNLinking>1083-7159</ISSNLinking>        </MedlineJournalInfo>        <CoiStatement>Disclosures of potential conflicts of interest may be found at the end of this article.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>20</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30297384</ArticleId>            <ArticleId IdType="pii">theoncologist.2018-0279</ArticleId>            <ArticleId IdType="doi">10.1634/theoncologist.2018-0279</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>